Denise Sutherland‐Phillips

High Sensitivity of Human Leukocyte Antigen–B*5701 as a Marker for Immunologically Confirmed Abacavir Hypersensitivity in White and Black Patients

Michael S. Saag, Rukmini Balu, Elizabeth J. Phillips et al. · Clinical Infectious Diseases · 2008 · 431 citations · Full text

Life Sciences, Dermatology, Immunology +12

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

Joseph J. Eron, Patrick Yéni, Joseph Gathe et al. · The Lancet · 2006 · 342 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment

Kimberly Y. Smith, Parul Patel, Derek M. Fine et al. · AIDS · 2009 · 217 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial

Moti Ramgopal, Antonella Castagna, Charles Cazanave et al. · The Lancet HIV · 2023 · 115 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America

Benjamin Young, Kathleen Squires, Parul Patel et al. · AIDS · 2008 · 98 citations

Life Sciences, Immunology, Pharmacotherapy +14